Jenburkt Pharmaceuticals Limited — a BSE-listed (script code 524731) Indian pharmaceutical company.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 4 |
| Reserves | 75 | 94 | 113 | 118 | 141 | 167 | 178 | 193 |
| Borrowings | 3 | 5 | 7 | 3 | 0 | 4 | 2 | 2 |
| Other Liabilities | 21 | 17 | 18 | 16 | 19 | 19 | 24 | 26 |
| Total Liabilities | 104 | 120 | 143 | 141 | 164 | 195 | 209 | 226 |
| AssetsFixed Assets | 12 | 11 | 11 | 10 | 10 | 15 | 14 | 19 |
| CWIP | 0 | 0 | 0 | 1 | 1 | 40 | 52 | 46 |
| Investments | 4 | 7 | 8 | 11 | 17 | 21 | 27 | 27 |
| Other Assets | 88 | 103 | 123 | 119 | 136 | 120 | 116 | 133 |
| Total Assets | 104 | 120 | 143 | 141 | 164 | 195 | 209 | 226 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 13 | 15 | 19 | 9 | 17 | 8 | 28 | 27 |
| Cash from Investing | -11 | -3 | -19 | -1 | 3 | -1 | -17 | -19 |
| Cash from Financing | -2 | -11 | -1 | -6 | -21 | -7 | -8 | -9 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 11 | 11 | 18 | 7 | 15 | 6 | 8 | 13 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (13.7×) and current (14.5×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 12.8% growth and a 14× exit, ₹1141 only delivers your return if you pay ₹877. The price is currently baking in 18% growth.
EPS grows 12.8%/yr for 5 years, then fades to 6% over 2, exits at 14×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 12.8% | 88.76 |
| FY28 | 12.8% | 100.12 |
| FY29 | 12.8% | 112.94 |
| FY30 | 12.8% | 127.40 |
| FY31 | 12.8% | 143.70 |
| FY32 | 9.4% ·fade | 157.21 |
| FY33 | 6.0% ·fade | 166.64 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.